MorphoSys welcomes Jean-Paul Kress as new CEO

First MorphoSys-antibody approved
Tremfya® (Guselkumab) now available in US, Europe and Canada!

We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.

Find out more about our therapeutic pipeline.

More Info

MorphoSys's vision

MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

learn more about the company

20/11/2019
Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His...
18/11/2019
MorphoSys' tafasitamab B-MIND DLBCL study successfully passed...
18/11/2019
Ad hoc: MorphoSys' tafasitamab B-MIND DLBCL study successfully passed...
15/11/2019
MorphoSys Continues to Build Commercial Presence by Opening new U.S....
11/11/2019
Results for Bimagrumab in Obesity and Type 2 Diabetes presented by...
06/11/2019
MorphoSys to Present Data on Tafasitamab at ASH 2019 Meeting
29/10/2019
MorphoSys AG Reports Third Quarter 2019 Financial Results
29/10/2019
MorphoSys AG: Primary Endpoint met in Real-World Data Study Demonstrating...
29/10/2019
MorphoSys AG: Ad hoc: Primary Endpoint met in Real-World Data Study...
28/10/2019
MorphoSys AG: MOR106 Clinical Development in Atopic Dermatitis Stopped

November 25, 2019
German Eigenkapitalforum
Frankfurt, Germany

See conference